反应 #66089

ord-e371a3fb99564f8e8868bf72c644bbd2

反应方程式

Brc1cccc2c3c([nH]c12)C1CCN(CC1)C3
product
Brc1cccc2c3c([nH]c12)C1CCN(CC1)C3
7-bromo-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole
OB(O)c1cncnc1
pyrimidine-5-boronic acid
c1cc(-c2cncnc2)c2[nH]c3c(c2c1)CN1CCC3CC1
title compound
c1cc(-c2cncnc2)c2[nH]c3c(c2c1)CN1CCC3CC1
7-(pyrimidin-5-yl)-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole

反应条件

详细条件
See reaction.notes.procedure_details.

实验过程

The product of Example 1B (100 mg, 0.32 mmol) and pyrimidine-5-boronic acid (64 mg, 0.52 mmol; MayBridge) were processed as described in Example 4 to provide the title compound: 1H NMR (500 MHz, methanol-d4) δ ppm 2.01-2.17 (m, 4 H), 2.60 (s, 3 H), 3.03-3.14 (m, 3 H), 3.20-3.29 (m, 2 H), 4.27 (s, 2 H), 7.03-7.06 (m, 1 H), 7.10 (t, J=7.6 Hz, 1 H), 7.34 (dd, J=7.6, 1.2 Hz, 1 H), 7.42 (d, J=8.2 Hz, 1 H), 7.96 (dd, J=7.9, 2.4 Hz, 1 H), 8.63 (d, J=2.1 Hz, 1 H); MS (ESI+) m/z 291 (M+H)+.

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: US08524703B2uspto-grants-2013_09